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Abstract

Background -- We evaluated a multifaceted, computerized quality improvement intervention for
management of cardiovascular disease (CVD) risk in Australian primary health care. After completion of a
cluster randomized controlled trial, the intervention was made available to both trial arms. Our objective was
to assess intervention outcomes in the post-trial period and any heterogeneity based on original intervention
allocation.
Methods and Results -- Data from 41 health services were analyzed. Outcomes were (1) proportion of
eligible population with guideline-recommended CVD risk factor measurements; and (2) the proportion at
high CVD risk with current prescriptions for guideline-recommended medications. Patient-level analyses
were conducted using generalized estimating equations to account for clustering and time effects and tests for
heterogeneity were conducted to assess impact of original treatment allocation. Median follow-up for 22 809
patients (mean age, 64.2 years; 42.5% men, 26.5% high CVD risk) was 17.9 months post-trial and 35 months
since trial inception. At the end of the post-trial period there was no change in CVD risk factor screening
overall when compared with the end of the trial period (64.7% versus 63.5%, P=0.17). For patients at high
CVD risk, there were significant improvements in recommended prescriptions at end of the post-trial period
when compared with the end of the trial period (65.2% versus 56.0%, P < 0.001). There was no heterogeneity
of treatment effects on the outcomes based on original randomization allocation.
Conclusions -- CVD risk screening improvements were not observed in the post-trial period. Conversely,
improvements in prescribing continued, suggesting that changes in provider and patient actions may take time
when initiating medications.
Disciplines

Medicine and Health Sciences | Social and Behavioral Sciences
Publication Details

Patel, B., Peiris, D., Usherwood, T., Li, Q., Harris, M., Panaretto, K., Zwar, N. & Patel, A. (2017). Impact of
sustained use of a multifaceted computerized quality improvement intervention for cardiovascular disease
management in Australian primary health care. Journal of the American Heart Association, 6 (10),
e007093-1-e007093-12.
Authors

Bindu Patel, David Peiris, Tim Usherwood, Qiang Li, Mark Harris, Kathryn S. Panaretto, Nicholas Arnold
Zwar, and Anushka Patel

This journal article is available at Research Online: http://ro.uow.edu.au/smhpapers/5043

ORIGINAL RESEARCH

Impact of Sustained Use of a Multifaceted Computerized Quality
Improvement Intervention for Cardiovascular Disease Management in
Australian Primary Health Care
Bindu Patel, MPH; David Peiris, MBBS, MIPH, PhD; Tim Usherwood, MBBS, MD; Qiang Li, MBiostat; Mark Harris, MBBS MD;

Kathryn Panaretto, MBBS, MPH; Nicholas Zwar, MBBS, PhD; Anushka Patel, MBBS, SM, PhD
Background-—We evaluated a multifaceted, computerized quality improvement intervention for management of cardiovascular
disease (CVD) risk in Australian primary health care. After completion of a cluster randomized controlled trial, the intervention was
made available to both trial arms. Our objective was to assess intervention outcomes in the post-trial period and any heterogeneity
based on original intervention allocation.
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Methods and Results-—Data from 41 health services were analyzed. Outcomes were (1) proportion of eligible population with
guideline-recommended CVD risk factor measurements; and (2) the proportion at high CVD risk with current prescriptions for
guideline-recommended medications. Patient-level analyses were conducted using generalized estimating equations to account for
clustering and time effects and tests for heterogeneity were conducted to assess impact of original treatment allocation. Median
follow-up for 22 809 patients (mean age, 64.2 years; 42.5% men, 26.5% high CVD risk) was 17.9 months post-trial and 35 months
since trial inception. At the end of the post-trial period there was no change in CVD risk factor screening overall when compared
with the end of the trial period (64.7% versus 63.5%, P=0.17). For patients at high CVD risk, there were signiﬁcant improvements in
recommended prescriptions at end of the post-trial period when compared with the end of the trial period (65.2% versus 56.0%,
P<0.001). There was no heterogeneity of treatment effects on the outcomes based on original randomization allocation.
Conclusions-—CVD risk screening improvements were not observed in the post-trial period. Conversely, improvements in
prescribing continued, suggesting that changes in provider and patient actions may take time when initiating medications.
Clinical Trial Registration-—URL: http://www.anzctr.org.au. Unique identiﬁer: 12611000478910. ( J Am Heart Assoc. 2017;6:
e007093. DOI: 10.1161/JAHA.117.007093.)
Key Words: cardiovascular disease prevention • computer decision support systems • health information technology
• intervention • long-term use • primary health care • quality improvement

Q

uality issues affecting healthcare organizations worldwide include inadequate access to healthcare services,
suboptimal provision of evidence-based preventive services
and treatments, and poor coordination of care across healthcare systems.1,2 Our previous work found that only around one
half of adults routinely attending Australian primary healthcare
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providers are screened for CVD risk in accordance with
guideline recommendations, and only about 40% of those
identiﬁed at high CVD risk are prescribed recommended
medications.3,4 Meaningful use of health information technology (HIT) has the potential to be an important enabler in
increasing the quality of healthcare delivery.5,6 Two such HIT
tools are computer decision support systems and computerized audit and feedback tools (the provision of summarized
clinical performance indicators to healthcare provider(s) over a
speciﬁed period of time). There is a well-established evidence
base demonstrating that these tools improve processes of care
and modestly improve clinical outcomes.7–10 Despite this
evidence, there remain substantial challenges in implementing
these tools in routine clinical care.11,12
We designed a computerized multifaceted quality improvement (QI) intervention for CVD risk management in Australian
primary health care. The intervention, termed HealthTracker,
comprised 4 elements: (1) real-time decision support
Journal of the American Heart Association
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understanding of the impact of integration of the intervention
into routine clinical care.

What Is New?
• This observational study examines the impact of a multifaceted computerized quality improvement intervention to
reduce cardiovascular disease risk beyond the randomized
trial period.
• The intervention in a post-trial period was associated with
maintenance of trial-related improvements in screening of
cardiovascular disease risk and ongoing improvements in
prescribing recommended medicines to patients at high
cardiovascular disease risk.

What Are the Clinical Implications?
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• The study demonstrates evidence of potential longer-term
impact of a computerized quality improvement intervention
on primary prevention of cardiovascular diseases.

integrated with the patient electronic record utilizing a
guidelines-based algorithm; (2) a patient risk communication
interface that included “what if scenarios” to show the
potential beneﬁts from particular health risk factor modiﬁcations during a consultation; (3) an automated clinical audit
tool for extraction of data and review of health service
performance; and (4) a web portal where services could view
peer-ranked performance over time. Details of the intervention have been published.13
HealthTracker was evaluated between 2011 and 2013 in
the TORPEDO (Treatment of Cardiovascular Risk in Primary
Care Sing Electronic Decision Support) study, a clusterrandomized controlled trial (cRCT) involving 38 725 people
from 60 primary healthcare services. Detailed results of the
study have been previously published.14 In brief, when
compared with services that did not have HealthTracker
installed, and after a median of 17.5 months follow-up,
services with HealthTracker demonstrated a 25% relative (10%
absolute) improvement in CVD risk factor screening. There
was no signiﬁcant difference overall in prescribing rates of
recommended medicines for people at high CVD risk.
However, for the subgroup of individuals at high CVD risk
who were not prescribed optimal recommended medicines at
baseline, the intervention was associated with a 59% relative
(17% absolute) improvement in prescribing rates.
At the completion of the trial, health services in both trial
arms were offered access to HealthTracker and invited to
participate in a post-trial evaluation. Randomized controlled
trials generally have short-term follow-up periods, and
evidence of sustained impact in nontrial settings is
sparse.15,16 In this observational study, we analyze changes
in CVD risk factor screening, prescribing to high-risk patients
and patient outcomes in this post-trial period to improve our
DOI: 10.1161/JAHA.117.007093

Methods
Intervention
Forty-ﬁve of the original 60 primary health services (29
general practices [GPs] and 16 Aboriginal community
controlled health services) agreed to participate in the
post-trial study (Figure 1). Fifteen health services chose not
participate because of the health service closing or moving
(n=4); limited resources (n=3); concerns about HIT tool
slowing down their computer system (n=3); changing to an
incompatible electronic health record software system
(n=3); using another online CVD risk tool (n=1); and lack
of interest (n=1). Four services later withdrew because of
concerns about resources required to support intervention
use and the effects of the software on the speed of their
systems, leaving 41 services (21 intervention and 20
control) included for evaluation purposes. The study population comprised Aboriginal and Torres Strait Islander
people aged ≥35 years and all others aged ≥45 years,
who were regular attendees of the health service. Regular
attendance was deﬁned as having visited the health service
at least 3 times in the preceding 2 years and once in the
preceding 6 months.
Health services that had been previously randomized to not
receive HealthTracker were trained in use of the intervention
at the end of the cRCT. The health services previously
randomized to receive HealthTracker were given a refresher at
the end of the cRCT period, if requested. Ongoing training and
technical support was provided to the health services on
request, but this was minimal during the post-trial period. An
average of 13-minute support per month comprising on-site
training, remote clinical Webinars, and IT helpdesk services
was provided during the post-trial period, 35 minutes less
than during the cRCT. All software was provided free of
charge.

Data Collection
Nonidentiﬁable data extracts were obtained from each service
using a validated extraction tool17 at 3 time points—(1) at
baseline for the cRCT; (2) at the end of the cRCT; and (3) at
the end of the post-trial period. Data extractions were either
conducted by the research team through a virtual remote login system or by health service staff themselves. Data were
sent via a secure ﬁle transfer protocol or encrypted email to
the coordinating research institute. An encrypted identiﬁer
code was added to each patient’s data, and this was used to
enable longitudinal follow-up of individual patients.
Journal of the American Heart Association
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61 health services randomized

31 randomized to intervention

30 randomized to control

(21GPs, 10 ACCHSs)
• 1 GP withdrew from the study shortly
after randomization

(20 GPs, 10 ACCHSs)

30 health services analyzed at end of cRCT
•

Median follow-up - 17.3 months (IQR
15.3-18.0)

30 health services analyzed at end of cRCT
•

Median follow-up - 17.7 months (IQR
14.3-18.3)
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7 – did not wish
to participate

8 – did not wish
to participate

(2 closed; 1
limited resources,
1 concerns about
system slowness;
2 changed to
incompatible
software system;
1 not interested)

(2 closed/moved;
2 limited
resources, 2
concerns about
system slowness;
1 changed to
incompatible
software system;
1 using another
online CVD risk
tool)

23 health services agreed to participate in
post-trial period

22 health services agreed to participate in
post-trial period
2 withdrew (1
limited
resources; 1
organizational
change)

2 withdrew (1
limited resources;
1 concerns about
system slowness
21 health services analyzed at end of post-trial
•
•

N = 12, 534
Median follow-up in post-trial phase
17.7 months (IQR 15.5-20.8)

20 health services analyzed at end of post-trial
•
•

N = 10, 275
Median follow-up in post-trial phase
18.5 months (IQR 15.6-23.1)

Figure 1. Study ﬂow diagram. ACCHS indicates Aboriginal Community Controlled Health Service; cRCT,
cluster randomized controlled trial; CVD, cardiovascular disease; GP, general practice; IQR, interquartile
range.

We invited all general practitioners (GPs) from the intervention health services to complete an end-of-study survey.
The survey obtained information on GP use of the intervention
along with their professional and health service characteristics and prior use of information technology.
The study was approved by The University of Sydney
Human Research Ethics Committee (2012/2183) and the
Aboriginal Health & Medical Research Council of New South
DOI: 10.1161/JAHA.117.007093

Wales (778/11). Participation agreements were signed
between the participating health services and the coordinating research institute.

Study Outcomes
The follow-up study outcomes were prespeciﬁed and correspond to those reported in the TORPEDO study. Co-primary
Journal of the American Heart Association

3

Long-Term Use of a Complex eHealth Intervention

Patel et al

Downloaded from http://jaha.ahajournals.org/ by guest on November 7, 2017

1. The proportion of eligible patients who received appropriate screening of CVD risk factors. Appropriate screening
was deﬁned as smoking status recorded at least once;
systolic blood pressure recorded in the previous
12 months; and total cholesterol and high-density lipoprotein recorded in the previous 24 months.
2. The proportion of eligible patients deﬁned at baseline as
being at high CVD risk, receiving recommended medications. This was deﬁned as (1) current medication of at
least 1 blood pressure (BP)–lowering drug and statin for
high-risk patients without established CVD, and (2) current
medication of at least 1 BP–lowering drug, statin, and
antiplatelet agent (unless contraindicated) for patients
with established CVD. This outcome was evaluated in the
overall high-risk cohort, as well as the subgroup of highrisk individuals who were undertreated (deﬁned as those
not prescribed guideline-recommended medications at
baseline).
3. Escalation of prescription medication (either newly prescribed or additional numbers of antiplatelet, BP–lowering
or lipid-lowering medications) among patients at high CVD
risk.
4. Change in BP and serum lipid levels among people at high
CVD risk.
Based on Australian guidelines, high CVD risk was deﬁned
as (1) history of CVD (diagnosis of coronary heart disease,
cerebrovascular disease, or peripheral vascular disease); (2)
the presence of any guideline-stipulated clinically high-risk
conditions such as diabetes mellitus and age >60 years,
diabetes mellitus and albuminuria, stage 3B chronic kidney
disease, or extreme individual risk factor elevations: systolic
BP ≥180 mm Hg, diastolic BP ≥110 mm Hg, total cholesterol
>7.5 mmol (290 mg/dL); or (3) a calculated 5-year CVD risk
of >15% based on the Framingham equation.18

Statistical Analysis
Analyses were performed on the cohort of patients for whom
data were recorded at baseline, end of the cRCT, and end of
the post-trial period. Descriptive data are presented as mean
(SEs) or proportions. Patient-level analysis was conducted
using generalized estimating equations to account for clustering of patients within services with exchangeable correlation structure. A v2 test for categorical variables was used to
test for comparison between intervention and control health
services since they are at the cluster level. The P value for
patient characteristics was obtained from the generalized
estimating equations model, taking into account the clustering effect using log link for binary variables and identity link
DOI: 10.1161/JAHA.117.007093

for continuous variables. The random allocation was the
independent variable in the model. Study outcome analyses
were conducted using generalized estimating equations
regression model for continuous outcome, assuming Gaussian
distribution and binary outcomes assuming binomial distribution with a log link function. Effect estimates between
intervention and usual care health services for the primary
and secondary outcomes were obtained from the generalized
estimating equations model with adjustments made for
baseline measurements, size of service, type of service, and
current participation in QI initiatives. Given that the event rate
is higher in our prospective study, the log link function was
used to produce a rate ratio between intervention and usual
care group rather than deriving an odds ratio using a logit link
function. Although odds ratios produced by logit link tend to
be equivalent to rate ratios produced by log link when the
event rate is small, they may overestimate the relative risk
when event rate is high.
Trend analysis was conducted using data from 2 time
points: end of cRCT and end of post-trial period. Additionally,
paired comparisons were performed to evaluate the effects
of receiving the intervention during the post-trial period. For
outcomes in the post-trial period, P values were calculated
based on change from end of the cRCT to the end of the
post-trial period. For the post-trial period, heterogeneity in
effects between the previously randomized intervention and
control groups was assessed based on the signiﬁcance of
interaction term in the model. Statistical analyses were
carried out using SAS enterprise guide 7.1 (SAS Institute Inc,
Cary, NC).

Results
Cohort
The original TORPEDO cRCT included 38 725 individuals from
60 health services with a median follow-up of 17.3 months for
the intervention group, and 17.7 months for the control
group. Of these, 22 809 patients from 41 health services
were followed up in the post-trial period. Twenty-one services
(n=12 534) were originally randomized to the intervention
and 20 services (n=10 275) to control (Figure 1).
For the screening outcome, data from the 3 extraction
periods for the overall post-trial cohort (22 809 patients) were
analyzed. For the prescribing outcome, data from the 3
extraction periods were analyzed for those patients identiﬁed
as high CVD risk patients at baseline in the cRCT (6106
patients in total and 3039 patients who were undertreated).
The median post-trial follow-up was 17.7 months for the
intervention group and 18.5 months for the control group.
Recruitment into cRCT commenced in September 2011 and
the ﬁnal health service data collection for the post-trial period
Journal of the American Heart Association

4

ORIGINAL RESEARCH

outcomes are 1 and 2, and secondary outcomes are 3 and 4
below:

Long-Term Use of a Complex eHealth Intervention

Patel et al

Table 1. Baseline Health Service Characteristics
Intervention
(N=21,
n=12 534)

Control
(N=20,
n=10 275)

P Value

<500

9/21 (42.9%)

9/20 (45.0%)

0.89

≥500

12/21 (57.1%)

11/20 (55.0%)

Aboriginal
community
controlled health
service

6/21 (28.6%)

6/20 (30.0%)

General practice

15/21 (71.4%)

14/20 (70.0%)

Best practice

5/21 (23.8%)

7/20 (35.0%)

Medical director

16/21 (76.2%)

13/20 (65.0%)

Health Service
Characteristics (n=41)

Demographics

Downloaded from http://jaha.ahajournals.org/ by guest on November 7, 2017

For those health services participating in the post-trial
period, there were no signiﬁcant differences in baseline
health service characteristics between the intervention and
control groups (Table 1). There was no difference in risk
factor screening and appropriate prescriptions for high CVD
risk patients based on our 3 prespeciﬁed health service
characteristics of health service type (Aboriginal Community
Controlled Health Service versus general practice), service
size (<500 and ≥500), and if health service participated in a
QI program prior to randomization. Table 2 compares patient
characteristics at baseline and at the end of the cRCT. With
the exception of albuminuria rates, the variables with
signiﬁcant between-group differences at the end of the
cRCT were similarly observed at baseline. Further, there
were no differences in the health services and patient
characteristics of those who participated and those who did
not participate in the post-trial period.

Eligible population

Type of services

Both local and
external

2/21 (9.5%)

8/20 (40.0%)

External

12/21 (57.2%)

8/20 (40.0%)

Local

7/21 (33.3%)

4/20 (20.0%)

0.07

Staff currently using data extraction tools
1/21 (4.8%)

None

9/21 (42.9%)

6/20 (30.0%)

Thirty-two GPs within 21 intervention health services (70%)
completed the end of study survey. Of these, 6% reported
always using the intervention, 25% used it more than half of
the time, 53% used it less than half of the time, and 15% never
used it for our study patient population. The majority of GPs
had positive attitudes to all intervention components (Figure 2).

Some

11/21 (52.4%)

14/20 (70.0%)

DOI: 10.1161/JAHA.117.007093

0.43

Information technology support

Most

There were no differences in appropriate CVD risk factor
screening rates during the post-trial period when compared
with rates at the end of the cRCT ([64.7% versus 63.5%
overall; P-trend=0.17] Figure 3). There was also no heterogeneity of effects by original intervention allocation group
(P=0.18). Thirty-ﬁve percent of patients were not screened
appropriately according to guideline recommendations at the
end of the post-trial period. Of these, 31.1% had insufﬁcient
data to calculate absolute CVD risk, 39.8% were low-risk
patients with missing or out-of-date information, and 29.1%
high-risk patients with missing or out-of-date information
among high-risk patients. The main driver for this was an outof-date or missing lipid value, which accounted for 71.3% of
the screening gap.
There was a signiﬁcant improvement in prescription rates
for patients at high CVD risk in the post-trial period when

0.92

Medical software used

Survey on Attitudes to the Software Tools

Outcomes

ORIGINAL RESEARCH

was completed in February 2015 (total median follow-up of
34.8 and 35.0 months for the intervention and control
groups, respectively).

0/20 (0.0%)

0.38

Current participation in a quality improvement initiative
No

14/21 (66.7%)

12/20 (60.0%)

Yes

7/21 (33.3%)

8/20 (40.0%)

0.66

compared with rates at the end of the cRCT ([65.2% versus
56.0% overall; P-trend<0.001] Figure 4). There was no
heterogeneity of effects by original intervention allocation
group (P=0.57).
There were signiﬁcant absolute increases in medication
escalation (new prescriptions or increased numbers of
medications) for patients at high CVD risk in the post-trial
period. An absolute improvement of 15.8% was observed for
antiplatelet drugs (P<0.01); 14.8% for lipid-lowering medications (P<0.01); and 19.0% for BP-lowering medications
(P<0.01). There was no heterogeneity in these outcomes by
original intervention allocation group.
For the high CVD risk patients who were undertreated (not
prescribed guideline-recommended medications) at baseline,
the prescribing rates of recommended medications prescriptions in the post-trial period was signiﬁcantly higher overall
compared with the rates at the end of the cRCT (42.1% versus
33.4%, P-trend<0.001). This improvement was apparent in
both the intervention and control groups (44.9% intervention
Journal of the American Heart Association

5

DOI: 10.1161/JAHA.117.007093

Journal of the American Heart Association

10 983
11 265
11 103
10 688
2062
8778

Current smoker or ex-smoker in the past
12 mo

Systolic BP (mm Hg), mean (SD)

Total cholesterol (mmol), mean (SD)

High-density lipoprotein (mmol), mean (SD)

HbA1c for those with recorded diagnosis of
diabetes mellitus, mean (SD)

Body mass index >30 kg/m2

12 533
12 533
12 533
12 533

Atrial fibrillation diagnosis recorded

Heart failure diagnosis recorded

12 533

Peripheral vascular diagnosis recorded

Left ventricular hypertrophy diagnosis
recorded

12 533

Cerebrovascular disease diagnosis
recorded

Diabetes mellitus diagnosis recorded

12 533

11 062

Coronary heart disease diagnosis
recorded

Recorded diagnosis

Estimated glomerular filtration rate
<60 mL/min per 1.73 m2‡

2405

12 534

Aboriginal/Torres Strait Islander

Albuminuria

12 531

Male

229 (1.8%)

482 (3.9%)

24 (0.2%)

2196 (17.5%)

97 (0.8%)

374 (3.0%)

1421 (11.3%)

1285 (11.6%)

657 (27.3%)

3304 (37.6%)

8.0 (4.9)

1.4 (0.4)

5.0 (1.1)

130.3 (16.1)

1967 (17.9%)

1636 (13.1%)

5649 (45.1%)

62.5 (12.3)

10 275

10 275

10 275

10 275

10 275

10 275

10 275

8768

2352

7511

1677

7702

8629

9743

9013

10 275

10 268

10 275

12 533

Age, mean (SD)

†

P Value

116 (1.1%)

318 (3.1%)

66 (0.6%)

1768 (17.2%)

93 (0.9%)

226 (2.2%)

989 (9.6%)

739 (8.4%)

569 (24.2%)

2681 (35.7%)

7.5 (1.8)

1.4 (0.4)

5.0 (1.1)

129.1 (17.3)

1838 (20.4%)

1726 (16.8%)

4056 (39.5%)

60.0 (11.4)

0.31

0.18

0.01*

0.87

0.90

0.11

0.12

0.01*

0.97

0.11

0.33

0.94

0.57

0.38

0.96

0.68

0.01

0.72

12 534

12 534

12 534

12 534

12 534

12 534

12 534

11 805

4087

9736

2280

11 582

11 887

12 036

11 650

12 534

12 534

12 534

N

286 (2.3%)

566 (4.5%)

31 (0.3%)

2367 (18.9%)

126 (1.0%)

432 (3.5%)

1598 (12.7%)

1545 (13.1%)

892 (21.8%)

3648 (37.5%)

12.7 (16.0)

1.4 (0.4)

4.9 (1.3)

129.7 (15.8)

1915 (16.4%)

1647 (13.1%)

5647 (45.1%)

63.9 (12.2)

n (%) or Mean (SE)

(Intervention=21, n=12 534)

N

n (%) or Mean (SE)

(Control=20, n=10 275)

N

n (%) or Mean (SE)

(Intervention=21, n=12 534)

Variable Name

End of cRCT (Sites n=41)

Baseline of cRCT (Sites n=41)

10 275

10 275

10 275

10 275

10 275

10 275

10 275

9450

3127

8269

1857

8582

9347

9929

9512

10 275

10 273

10 275

N

175 (1.7%)

405 (3.9%)

79 (0.8%)

1919 (18.7%)

113 (1.1%)

270 (2.6%)

1119 (10.9%)

925 (9.8%)

763 (24.4%)

2879 (34.8%)

8.4 (7.3)

1.4 (0.4)

5.0 (1.1)

129.0 (17.0)

1747 (18.4%)

1747 (17.0%)

4054 (39.5%)

61.3 (11.4)

n (%) or Mean (SE)

(Control=20, n=10 275)

0.66

0.64

0.01*

0.86

0.83

0.10

0.17

0.02*

0.04*

0.10

0.42

0.91

0.21

0.72

0.92

0.68

0.01*

0.71

P Value

Continued

ORIGINAL RESEARCH
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12 534

>15%

P Value

773 (42.6%)

961 (55.5%)

1814

1733

Current prescription for at least 1 BPlowering medication and a statin for
people at high CVD risk

Current prescription for at least 1 BPlowering medication, a statin and an
antiplatelet agent for people with CVD

1209

1350

2559

10 275

10 275

10 275

10 275

10 275

10 275

715 (59.1%)

618 (45.8%)

1333 (52.1%)

1209 (11.8%)

1096 (10.7%)

254 (2.5%)

537 (5.2%)

4138 (40.3%)

3041 (29.6%)

0.95

0.54

0.67

0.19

0.30

0.53

0.19

0.79

0.28

1733

1783

3516

12 534

12 534

12 534

12 534

12 534

12 534

N

978 (56.4%)

1057 (59.3%)

2035 (57.9%)

1963 (15.7%)

1578 (12.6%)

419 (3.3%)

922 (7.4%)

5915 (47.2%)

1737 (13.9%)

n (%) or Mean (SE)

1209

1305

2514

10 275

10 275

10 275

10 275

10 275

10 275

N

603 (49.9%)

738 (56.6%)

1341 (53.3%)

1374 (13.4%)

1191 (11.6%)

280 (2.7%)

639 (6.2%)

4769 (46.4%)

2022 (19.7%)

n (%) or Mean (SE)

(Control=20, n=10 275)

0.08

0.27

0.17

0.21

0.27

0.19

0.43

0.42

0.02*

P Value

BP indicates blood pressure; cRCT, cluster randomized controlled trial; CVD, cardiovascular disease; HbA1c, glycated hemoglobin.
*Statistical signiﬁcance (P≤0.05).
†
Urinary albumin:creatinine ratio >2.5 men and >3.5 women.
‡
Calculated using the Chronic Kidney Disease Epidemiology Collaboration formula.
§
Calculated using the 1991 Anderson Framingham risk equation.
k
Any of the following based on Australian guidelines: diabetes mellitus and age >60 y, diabetes mellitus and albuminuria, estimated glomerular ﬁltration rate <45 mL/min per 1.73 m2, systolic BP ≥180 mm Hg, diastolic BP ≥110 mm Hg,
total cholesterol >7.5 mmol/L.
¶
Any of the following: coronary heart disease, cerebrovascular disease, and peripheral vascular disease.

1734 (48.9%)

1733 (13.8%)

3547

12 534

1461 (11.7%)

353 (2.2%)

850 (6.8%)

4966 (39.6%)

3171 (25.3%)

Eligible patients assessed at high CVD
risk receiving appropriate prescriptions
for their CVD risk factors at baseline

Primary outcomes at baseline

CVD diagnosis

¶

12 534

12 534

10%–15%

Clinically high-risk condition

12 534

<10%

k

12 534

n (%) or Mean (SE)

N

N

n (%) or Mean (SE)

(Intervention=21, n=12 534)

(Control=20, n=10 275)

(Intervention=21, n=12 534)

Missing information

CVD risk assessment

§

End of cRCT (Sites n=41)

Baseline of cRCT (Sites n=41)
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HealthTracker tool
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# of GPs

20

15

10

5

0
Overall
HealthTracker was
easy to use

Downloaded from http://jaha.ahajournals.org/ by guest on November 7, 2017

Calculaon of the Recommendaons Recommendaons
The CVD risk
Overall, Health
I would like to use
CVD risk score
for screening helped for treatment helped projecon graph
Tracker-CVD
HealthTracker aer
helped me to
me to improve
me to improve
increased paents increased the quality the study ﬁnishes
improve quality of
quality of care
quality of care
awareness of their
of my interacon
care
heart health

Strongly Disagree

Disagree

Neutral

Agree

Strongly Agree

Figure 2. General practitioner’s opinion on HealthTracker intervention use. CVD indicates cardiovascular
disease.

versus 37.8% control at post-trial period; Figure 5); however,
there was signiﬁcant heterogeneity by original intervention
allocation group (P=0.03), with greater effects observed in the
control arm. There were no changes in BP or cholesterol levels

in the post-trial period compared with mean levels at the end
of cRCT for either high-risk patients or undertreated high-risk
patients. There was no heterogeneity between patient
outcomes based on original randomization.

Figure 3. Patients receiving appropriate screening of their CVD risk factors. CVD indicates cardiovascular
disease; cRCT, cluster-randomized controlled trial.
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Figure 4. High CVD risk (>15% and with CVD) patients receiving recommended medications. CVD
indicates cardiovascular disease; cRCT, cluster-randomized controlled trial.

Discussion
Implementation of HealthTracker, a multifaceted QI intervention, in a post-trial setting was associated with maintenance
of trial-related improvements in CVD risk factor

measurements and ongoing improvements in prescription of
appropriate medications to patients at high CVD risk.
Sustainability of health innovations has been deﬁned as “the
extent to which desired health beneﬁts are maintained or
improved upon over time after initial funding or support have

Figure 5. Undertreated high CVD risk (>15% and with CVD) patients receiving recommended
medications. CVD indicates cardiovascular disease.
DOI: 10.1161/JAHA.117.007093
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the possibility that the intervention was able to address
doctor therapeutic inertia (deﬁned as failure to initiate or
increase medication when treatment goals are not being
met).26 Given the multifaceted nature of the intervention, it
can be difﬁcult to assess what were the “active ingredients”
that may have promoted improvements in prescribing
recommended treatments.
An important study limitation is that for technical reasons we
were unable to obtain usage data for the various intervention
tools. Based on GPs’ opinions on use of the intervention in the
end-of-study survey it would, however, appear that the intervention was partially used and when used the GPs viewed the
intervention favorably. To better understand implementation
issues, a detailed mixed-methods process evaluation of both
the trial and post-trial phases is under way to better understand
which intervention components promoted or had minimal
impact on behavior change at the provider, patient, and system
levels. We are capturing insights on usage patterns through
staff surveys, in-depth practitioner and patient interviews, and
ethnographic analyses of videotaped consultations.27,28 A
realistic evaluation approach is being taken to analyze the
mechanisms of change, contextual inﬂuences, and the resultant
outcomes.28,29 Preliminary ﬁndings indicate a complex interaction between the intervention, organizational mission and
values, the role of leaders and teams, and the technical
competence of the software tools. Understanding these
interactions is expected to shed further light on why mixed
outcomes are often observed with implementation strategies to
improve healthcare quality.
Despite an abundance of research on HIT interventions,
most studies are limited by examining short-term impact.
Consequently, knowledge on their implementation into routine
practice and sustainability of their use is sparse.30 Studies have
found that implementation of interventions outside of a trial
setting is inﬂuenced by several inter-related factors including
hardware and software computing infrastructure, clinical content, human–computer interface, people, workﬂow and communication, internal organizational policies and procedures and
culture, external rules and regulations and pressures, and
system measurement and monitoring.31 Some of these factors
will be addressed in the process evaluation. For future HIT
studies, these factors need to be evaluated on an ongoing basis
for successful implementation of HIT.
Study strengths include pragmatic implementation of the
intervention within routine clinical practice, evaluation in a
large cohort, and longer follow-up after initial implementation
during the post-trial period. The representativeness of the
general practices and Aboriginal community controlled health
services in Australia32,33 helps strengthen the generalizability
of the ﬁndings to similar healthcare environments in Australia.
The main study limitation is related to the lack of a
comparable control group during the post-trial period.34 This
Journal of the American Heart Association
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been withdrawn.”19,20 From this perspective, our ﬁndings
provide some indication of sustainability of the HealthTracker
intervention in the Australian primary healthcare environment.
A post-trial plateauing in CVD risk factor screening rates
was observed at health services in both trials arms. Despite
our evidence-based QI intervention being available, there
remained an overall CVD screening gap of 35%. The plateauing of CVD risk factor screening is suggestive of a “ceiling”
effect.18 There are some factors that partly explain this
phenomenon. Of the 35% screening gap, the vast majority had
an out-of-date or missing lipid value. The majority of out-ofdate values were from those identiﬁed at low CVD risk, and
providers may have not considered it necessary to re-screen
these patients within a 2-year timeframe. Although absolute
CVD risk assessment is recommended 2-yearly for low-risk
individuals in Australia,18 some guidelines recommend lipid
screening every 5 years.21 For those at moderate to high risk
who are lacking lipid measurements, there are possibly
patient factors (eg, difﬁcult-to-reach populations, refusal to be
tested) and provider factors (active disregard or passive
omission) at play.
Conversely, there was a signiﬁcant improvement in
recommended prescribing of appropriate treatments among
those at high CVD risk in the post-trial period both for the
intervention and control groups. The delayed onset of
improvement in the intervention group might be related to
doctors not prescribing recommended medications immediately following institution of lifestyle change recommendations or initiatives, or a generally more cautious approach to
introducing or accepting new treatments.22 The improvement
in prescriptions in the control group during the post-trial
period suggests the intervention had an impact outside the
trial setting, although there are obvious limitations in making
this assertion given the observational and uncontrolled nature
of the study design. The secular effects of wider distribution
of a new guideline advocating for an absolute risk approach to
management of cardiovascular risk may have also had
relevance to the observed change.18,23
The group that continued to have the most beneﬁt was the
undertreated high CVD risk patients. The intervention group
had signiﬁcant improvements in prescribing recommended
treatments both in the trial and post-trial period and the
control group signiﬁcantly improved in prescribing after
introduction of the intervention.
HealthTracker contains components known to improve
processes of care and outcomes in trial settings.9,24,25 Key
features include real-time, computer-guided decision support
that is integrated into routine clinical workﬂows, patientspeciﬁc recommendations and management rather than
assessments alone, screening and therapy alerts, and regular
audit and feedback advice to practitioners.14 The continued
escalation of medication in those at high CVD risk suggests
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